BRIEF-GRI Bio Completes Enrollment In Phase 2A Study Of GRI-0621 For The Treatment Of Idiopathic Pulmonary Fibrosis (“IPF”)
Reuters
Jul 01, 2025
BRIEF-GRI Bio Completes Enrollment In Phase 2A Study Of GRI-0621 For The Treatment Of Idiopathic Pulmonary Fibrosis (“IPF”)
July 1 (Reuters) - GRI Bio Inc GRI.O:
GRI BIO COMPLETES ENROLLMENT IN PHASE 2A STUDY OF GRI-0621 FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (“IPF”)
GRI BIO INC - TOPLINE RESULTS FROM PHASE 2A STUDY EXPECTED IN Q3 2025
GRI BIO INC - GRI-0621 DEMONSTRATED SAFE AND WELL-TOLERATED IN INTERIM SAFETY RESULTS
Source text: ID:nGNXg0PQz
Further company coverage: GRI.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.